ATX 70: structure given in first source; a gallium-porphyrin complex [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 164378 |
| MeSH ID | M0218403 |
| Synonym |
|---|
| 2,4-bis(1-decyloxyethyl)-ga(iii)-1,3,5,8-tetramethylporphyrin-6,7-dipropionyl diaspartic acid |
| atx-70 |
| gallate(3-), ((n,n'-((7,12-bis(1-(decyloxy)ethyl)-3,8,13,17-tetramethyl-21h,23h-porphine-2,18-diyl)bis(1-oxo-3,1-propanediyl))bis(l-aspartato))(6-)-n21,n22,n23,n24)-, trihydrogen, (sp-4-2)- |
| atx 70 |
| 135099-39-7 |
| gallium;2-[3-[8,13-bis(1-decoxyethyl)-18-[3-(1,2-dicarboxylatoethylamino)-3-oxopropyl]-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoylamino]butanedioate;hydron |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Short-lived toxic intermediates produced from ATX-70 by ultrasound are implicated in the mechanism, since no cytotoxicity was found when medium containing ATX-70 was sonicated and subsequently added to the cells." | ( Sonodynamic toxicity of gallium-porphyrin analogue ATX-70 in human leukemia cells. MisÃk, V; Miyoshi, N; Riesz, P, 1997) | 0.3 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The timing of 24 h after the administration of ATX-70 was chosen for ultrasonic exposure, based on pharmacokinetic analysis of ATX-70 concentrations in the tumor, plasma, skin, and muscle." | ( Sonodynamic therapy on chemically induced mammary tumor: pharmacokinetics, tissue distribution and sonodynamically induced antitumor effect of gallium-porphyrin complex ATX-70. Okuyama, N; Sasaki, K; Umemura, S; Yumita, N, 2007) | 0.34 |
| Excerpt | Reference | Relevance |
|---|---|---|
| "The antitumor effect of focused ultrasound in combination with Ga-porphyrin complex, 7,12-bis(1-decyloxyethyl)-Ga(III)-3,8,13,17 tetramethylporphyrin-2,18-dipropionyl diaspartic acid (ATX-70), on the growth of experimental murine tumors was examined." | ( Antitumor effect sonodynamically induced by focused ultrasound in combination with Ga-porphyrin complex. Nishigaki, R; Sasaki, K; Umemura, S; Yumita, N, 1998) | 0.3 |
| "The anti-tumor effects of high-energy shock waves (HESW) in combination with cisplatin (CDDP) and ATX-70, as a photosensitizer, were investigated in vitro and in vivo." | ( Application of high energy shock waves to cancer treatment in combination with cisplatin and ATX-70. Asano, T; Hasegawa, M; Isono, K; Iwashita, C; Maruyama, M; Miyauchi, H; Nakagohri, T; Uematsu, T, ) | 0.13 |
| " The anti-tumor effects of HESW in combination with cisplatin (CDDP) and ATX-70 was investigated in vitro and in vivo." | ( Application of high energy shock waves to cancer treatment in combination with cisplatin and ATX-70. Asano, T; Hasegawa, M; Isono, K; Iwashita, C; Maruyama, M; Miyauchi, H; Nakagohri, T; Uematsu, T, ) | 0.13 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (46.67) | 18.2507 |
| 2000's | 6 (40.00) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.
| This Compound (36.71) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (5.56%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (94.44%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||